Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.23 - $1.74 $29,712 - $224,780
129,184 New
129,184 $65,000
Q2 2023

Aug 14, 2023

BUY
$1.5 - $3.04 $22,891 - $46,393
15,261 New
15,261 $24,000
Q4 2022

Feb 14, 2023

BUY
$2.85 - $5.18 $230,268 - $418,523
80,796 Added 682.8%
92,629 $303,000
Q3 2022

Nov 14, 2022

BUY
$2.85 - $8.73 $33,724 - $103,302
11,833 New
11,833 $45,000
Q4 2021

Feb 14, 2022

SELL
$14.7 - $19.89 $3.62 Million - $4.9 Million
-246,136 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$11.99 - $17.9 $2.85 Million - $4.25 Million
-237,314 Reduced 49.09%
246,136 $4.41 Million
Q2 2021

Aug 16, 2021

SELL
$12.89 - $16.58 $6.09 Million - $7.83 Million
-472,259 Reduced 49.41%
483,450 $7.52 Million
Q1 2021

May 17, 2021

SELL
$14.0 - $20.72 $557,032 - $824,407
-39,788 Reduced 4.0%
955,709 $13.7 Million
Q4 2020

Feb 16, 2021

BUY
$12.67 - $26.23 $5.87 Million - $12.2 Million
463,626 Added 87.17%
995,497 $19.5 Million
Q3 2020

Nov 16, 2020

BUY
$11.92 - $15.87 $4.93 Million - $6.56 Million
413,217 Added 348.25%
531,871 $6.89 Million
Q2 2020

Aug 14, 2020

BUY
$7.53 - $14.93 $283,512 - $562,129
37,651 Added 46.48%
118,654 $1.73 Million
Q1 2020

May 15, 2020

SELL
$5.69 - $17.78 $908,283 - $2.84 Million
-159,628 Reduced 66.34%
81,003 $689,000
Q4 2019

Feb 14, 2020

BUY
$10.89 - $16.79 $1.61 Million - $2.48 Million
147,799 Added 159.21%
240,631 $3.96 Million
Q3 2019

Nov 14, 2019

BUY
$12.03 - $19.94 $1.12 Million - $1.85 Million
92,832 New
92,832 $1.31 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.